Wockhardt gets zero USFDA observations for Bioequivalence centre

Bioequivalence studies of Tamsulosin 0.4mg capsules and Metoprolol Tartrate 200mg ER tablets were audited, Wockhardt had reported.

New Delhi: Shares of drugmaker Wockhardt Ltd rise as much as 2.3 per cent to Rs 460, their highest since April 8.

The company says no observations made after the USFDA inspects its Bioequivalence centre in Aurangabad, Maharashtra.

Bioequivalence studies of Tamsulosin 0.4mg capsules and Metoprolol Tartrate 200mg ER tablets were audited, the company had reported.

Read Also: Wockhardt gets USFDA nod for Decitabine injection to treat cancer

About 425,970 shares change hands in less than half an hour into trading compared with the 30-day average volume of around 1.9 million.

Headquartered in Mumbai, the company has manufacturing plants in India, UK, Ireland, France and the US, and subsidiaries in the US, UK, Ireland and France.

It is a global company with more than half of its revenue coming from Europe. The company was founded by Dr Habil Khorakiwala in the 1960s

Read Also: Wockhardt gets USFDA nod for Abiraterone Acetate to treat prostate cancer